Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL PHARMACIE SONCIN COURSELLE : revenue, balance sheet and financial ratios

SELARL PHARMACIE SONCIN COURSELLE is a French company founded 7 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in LILLE (59000), this company of category PME shows in 2022 a revenue of 1.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE SONCIN COURSELLE (SIREN 840723985)
Indicator 2025 2024 2023 2022 2021 2020 2019
Revenue N/C N/C N/C 1 579 113 € N/C N/C N/C
Net income 89 051 € 110 948 € 56 854 € 135 327 € 134 690 € 88 431 € -11 823 €
EBITDA N/C N/C N/C 212 245 € N/C N/C N/C
Net margin N/C N/C N/C 8.6% N/C N/C N/C

Revenue and income statement

In 2025, SELARL PHARMACIE SONCIN COURSELLE generates positive net income of 89 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

89 051 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 72%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 51%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

71.604%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

51.201%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

29.3%

Solvency indicators evolution
SELARL PHARMACIE SONCIN COURSELLE

Sector positioning

Debt ratio
71.6 2025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Average -8 pts over 3 years

In 2025, the debt ratio of SELARL PHARMACIE SONCIN C... (71.60) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
51.2% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Average +9 pts over 3 years

In 2025, the financial autonomy of SELARL PHARMACIE SONCIN C... (51.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 203.97. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

203.97

Liquidity indicators evolution
SELARL PHARMACIE SONCIN COURSELLE

Sector positioning

Liquidity ratio
203.97 2025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Good

In 2025, the liquidity ratio of SELARL PHARMACIE SONCIN C... (203.97) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELARL PHARMACIE SONCIN COURSELLE

Positioning of SELARL PHARMACIE SONCIN COURSELLE in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of SELARL PHARMACIE SONCIN COURSELLE is estimated at 1 414 585 € (range 959 944€ - 2 219 679€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
959k€ 1414k€ 2219k€
1 414 585 € Range: 959 944€ - 2 219 679€
NAF 5 année 2025

Valuation method used

Net Income Multiple
89 051 € × 15.9x = 1 414 586 €
Range: 959 945€ - 2 219 680€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE SONCIN COURSELLE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE SONCIN COURSELLE

What is the revenue of SELARL PHARMACIE SONCIN COURSELLE ?

The revenue of SELARL PHARMACIE SONCIN COURSELLE in 2022 is 1.6 M€.

Is SELARL PHARMACIE SONCIN COURSELLE profitable?

Yes, SELARL PHARMACIE SONCIN COURSELLE generated a net profit of 89 k€ in 2025.

Where is the headquarters of SELARL PHARMACIE SONCIN COURSELLE ?

The headquarters of SELARL PHARMACIE SONCIN COURSELLE is located in LILLE (59000), in the department Nord.

Where to find the tax return of SELARL PHARMACIE SONCIN COURSELLE ?

The tax return of SELARL PHARMACIE SONCIN COURSELLE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE SONCIN COURSELLE operate?

SELARL PHARMACIE SONCIN COURSELLE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.